Abzena announced as best CRO at World ADC awards

Abzena is a leading partner research organisation that offers discovery, design, development and cGMP manufacture of biologics, bioconjugates and complex or highly potent small molecules to the global biopharmaceutical industry

Abzena, a fully integrated global development and GMP manufacturing partner for the biopharmaceutical industry, has been announced as the winner of the Best Contract Research (CRO) category at the World ADC Awards 2020.

The World ADC awards recognise innovation, leadership and devotion in the field of ADCs and include nine categories designed to acknowledge the extraordinary work and commercial acumen that companies have demonstrated to propel these therapeutics to the forefront of cancer research.

Commenting on the award win, Kimball Hall, Chief Operating Officer at Abzena said: “This is a tremendous achievement for the whole team at Abzena. It is testament to the continuous hard work of our employees and the great science and innovative solutions they deliver to our customers every day."

“We’re dedicated to the work we do with our customers and recognise that it could be invaluable when it comes to finding new oncology treatments, as well as potential medications for other therapeutic areas. It’s great to have that commitment and the quality of our work acknowledged.”

Abzena provides outsourced solutions from concept to clinic and into GMP manufacturing.

The company utilises a broad range of conjugation technologies to produce fully characterised ADCs from low mg to kg scale with all known cytotoxins, release mechanisms and polymers. Using their extensive expertise, Abzena successfully help customers to select ADC candidates with the best properties to promote success in the clinic.

Companies